Zabrina Watkins Radical welcomeness “At Prime we’re committed to creating an open, inclusive culture that’s purpose-oriented and focused on providing meaningful work for our employees. To do this,...

Sept. 27, 2024 - ustekinumab-aauz (Otulfi) Fresenius Kabi has received FDA approval for Otulfi as a biosimilar to ustekinumab (Stelara). This human interleukin (IL)-12 and IL-23 antagonist is...

Oncology Insights On May 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to intravenous Imdelltra™ (tarlatamab) for the treatment of adults with relapsed/refractory...

Prime’s Special Investigations Unit is specially trained to protect patients and providers throughout the health care continuum

March 7, 2025 – rivaroxaban 2.5 mg tablet (Xarelto) Lupin launched a generic to Janssen’s Xarelto Factor Xa inhibitor indicated (1) to reduce the risk of major cardiovascular events in patients...

Tennessee In accordance with Texas Senate Bill 1236, Prime Therapeutics provides Texas-based pharmacies with secure online access to their pharmacy benefit network contracts that were executed on...

Jessica Johnson, clinical consultant at Prime Therapeutics, shares some ways to avoid common fraud schemes

Heading Example Home Other Navigation Pharmacy + Providers Commercial Formularies Commercial formularies PrimeChoice Accord™ Formulary PrimeChoice Accord™ Formulary Updates NetResults™ A-Series...